X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EVT801 is a highly selective small molecule VEGFR3 tyrosine kinase inhibitor targeting tumour angiogenesis. It is being evaluated for the treatment of advanced solid tumours in adults.
Lead Product(s): EVT801
Therapeutic Area: Oncology Product Name: EVT801
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2024
Details:
GDC-0084 (paxalisib) is an oral PI3K/mTOR dual inhibitor, which is being evaluated for the treatment of patients with PI3K pathway mutation brain metastases.
Lead Product(s): Paxalisib
Therapeutic Area: Oncology Product Name: GDC-0084
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2024
Details:
GDC-0084 (paxalisib) is a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer.
Lead Product(s): Paxalisib
Therapeutic Area: Oncology Product Name: GDC-0084
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2023
Details:
GDC-0084 (paxalisib), a brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, is being developed to treat multiple forms of brain cancer. The direct anti-cancer effects of PI3K inhibitors are well demonstrated, and five therapies have been approved by the US FDA.
Lead Product(s): Paxalisib
Therapeutic Area: Oncology Product Name: GDC-0084
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: QIMR Berghofer Medical Research Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 15, 2022
Details:
EVT801 is an inhibitor of vascular endothelial growth factor receptors (VEGFR), which play an important role in angiogenesis and lymphangiogenesis (processes that contribute to tumor growth and metastasis), making VEGFR a well-established therapeutic target.
Lead Product(s): EVT801
Therapeutic Area: Oncology Product Name: EVT801
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Evotec
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2022
Details:
EVT801, a small-molecule, is a selective inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3). EVT801 was confirmed in preclinical studies to be a potent and selective inhibitor of VEGFR3, with activity in the low nanomolar range.
Lead Product(s): EVT801
Therapeutic Area: Oncology Product Name: EVT801
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
The safety profile of paxalisib in combination was broadly consistent with monotherapy experience in other clinical trials, and a maximum tolerated dose (MTD) of 45mg daily in combination with radiotherapy was confirmed.
Lead Product(s): Paxalisib
Therapeutic Area: Oncology Product Name: GDC-0084
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2022
Details:
GDC-0084 (paxalisib), a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.
Lead Product(s): Paxalisib
Therapeutic Area: Oncology Product Name: GDC-0084
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Global Coalition for Adaptive Research
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
INT230-6 (Paxalisib), a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, the safety profile of drug was highly consistent with previous clinical studies: hyperglycaemia, oral mucositis, and skin rash were among the most common drug-related toxicities.
Lead Product(s): Paxalisib
Therapeutic Area: Oncology Product Name: GDC-0084
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2022
Details:
At the outset, all patients will be treated with ONC201, combined with either paxalisib or panobinostat. The study employs an adaptive design, in which different arms will be opened and closed based on emerging preclinical and clinical data.
Lead Product(s): ONC201,Paxalisib
Therapeutic Area: Oncology Product Name: ONC201
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pacific Pediatric Neuro-Oncology Consortium
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
